Ancora Heart’s AccuCinch System Shows Sustained Reverse Remodeling at 2 Years 

October 24, 2025—Ancora Heart, Inc. announced the publication of 2-year outcomes from early clinical studies of its AccuCinch transcatheter left ventricular restoration system.

According to the company, the analysis demonstrated sustained reverse remodeling through 2 years, with associated improvements in cardiac function, quality of life, and reduced heart failure hospitalizations.

The findings were published by Alena Kurlianskaya, MD, et al in Structural Heart. The data included findings from 51 symptomatic patients with heart failure with reduced ejection fraction (HFrEF) treated at multiple centers in the United States and Europe.

As summarized in Ancora Heart’s press release, the investigators reported the following:

• Mean decrease in left ventricular end-diastolic volume of 30.0 ± 38.8 mL (P < .001).
• Mean increase in ejection fraction of 5.4 ± 9.0% (P < .001).
• Median 19.5-point rise in Kansas City Cardiomyopathy Questionnaire score (P < .001).
• Improvement by at least one New York Heart Association class in 60% of patients; 98% of patients either improved or remained stable.
• The rate of heart failure hospitalization was significantly reduced compared with the year preceding implantation (P < .001).

“Reverse remodeling is usually associated with reduced heart failure events and mortality,” commented study investigator Daniel Burkhoff, MD, in Ancora Heart’s press release. “From a clinical perspective, the fact that reverse remodeling is maintained at 2 years is particularly meaningful.” Dr. Burkhoff is Director of Heart Failure, Hemodynamics, and MCS Research at the Cardiovascular Research Foundation in New York, New York.

The company noted that patients in this 2-year analysis met key inclusion criteria (left ventricular ejection fraction 20-40%; mitral regurgitation ≤ 2+) for the ongoing CORCINCH-HF pivotal trial, which is expected to enroll 400 patients and will evaluate the safety and effectiveness of the AccuCinch device for patients with HFrEF.